Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors.

FAM181A FAM181B TEAD YAP hippo pathway nervous system omega loop protein-protein interaction

Journal

Protein science : a publication of the Protein Society
ISSN: 1469-896X
Titre abrégé: Protein Sci
Pays: United States
ID NLM: 9211750

Informations de publication

Date de publication:
02 2020
Historique:
received: 04 09 2019
accepted: 04 11 2019
pubmed: 8 11 2019
medline: 22 12 2020
entrez: 8 11 2019
Statut: ppublish

Résumé

The Hippo pathway is a key signaling pathway in the control of organ size and development. The most distal elements of this pathway, the TEAD transcription factors, are regulated by several proteins, such as YAP (Yes-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and VGLL1-4 (Vestigial-like members 1-4). In this article, combining structural data and motif searches in protein databases, we identify two new TEAD interactors: FAM181A and FAM181B. Our structural data show that they bind to TEAD via an Ω-loop as YAP/TAZ do, but only FAM181B possesses the LxxLF motif (x any amino acid) found in YAP/TAZ. The affinity of different FAM181A/B fragments for TEAD is in the low micromolar range and full-length FAM181A/B proteins interact with TEAD in cells. These findings, together with a recent report showing that FAM181A/B proteins have a role in nervous system development, suggest a potential new involvement of the TEAD transcription factors in the development of this tissue.

Identifiants

pubmed: 31697419
doi: 10.1002/pro.3775
pmc: PMC6954708
doi:

Substances chimiques

Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-520

Informations de copyright

© 2019 The Protein Society.

Références

Elife. 2017 Apr 21;6:
pubmed: 28430104
FEBS Lett. 2019 Feb;593(3):253-276
pubmed: 30570758
ACS Med Chem Lett. 2014 Jul 14;5(9):993-8
pubmed: 25221655
Structure. 2012 Jul 3;20(7):1135-40
pubmed: 22632831
Chembiochem. 2013 Jul 8;14(10):1218-25
pubmed: 23780915
Cancer Cell. 2014 Feb 10;25(2):166-80
pubmed: 24525233
Dev Genes Evol. 2016 Jul;226(4):297-315
pubmed: 27116603
Cancer Cell. 2016 Jun 13;29(6):783-803
pubmed: 27300434
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Science. 1986 Nov 14;234(4778):849-55
pubmed: 3775366
Chembiochem. 2014 Mar 3;15(4):537-42
pubmed: 24504694
Hum Mol Genet. 2004 May 1;13(9):975-81
pubmed: 15016762
Cancers (Basel). 2018 Mar 20;10(3):
pubmed: 29558384
Genes Dev. 2010 Feb 1;24(3):290-300
pubmed: 20123908
Genes Dev. 2010 Feb 1;24(3):235-40
pubmed: 20123905
Protein Cell. 2010 Dec;1(12):1073-83
pubmed: 21213102
J Biol Chem. 2000 Oct 6;275(40):30801-5
pubmed: 10934189
Sci Rep. 2017 May 17;7(1):2035
pubmed: 28515457
FEBS Lett. 2014 Jan 21;588(2):236-46
pubmed: 24211444
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W460-4
pubmed: 17567614
Nat Rev Cardiol. 2018 Nov;15(11):672-684
pubmed: 30111784
FASEB J. 1995 Jun;9(9):708-17
pubmed: 7601335
Mol Oncol. 2019 Jun;13(6):1335-1341
pubmed: 31050214
Biochemistry. 2015 Nov 3;54(43):6555-66
pubmed: 26465056
Mol Biol Evol. 2011 Aug;28(8):2403-17
pubmed: 21415026
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Gene. 2016 Oct 10;591(1):292-303
pubmed: 27421669
J Med Chem. 2015 Jun 25;58(12):4857-73
pubmed: 25719868
Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226
pubmed: 30546055
Dev Dyn. 1998 Jul;212(3):423-36
pubmed: 9671946
Protein Cell. 2017 May;8(5):349-359
pubmed: 28130761
Gene. 2016 Jan 10;575(2 Pt 2):438-451
pubmed: 26407640
Protein Sci. 2018 Oct;27(10):1810-1820
pubmed: 30058229
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Protein Expr Purif. 2003 Apr;28(2):362-7
pubmed: 12699702
J Mol Biol. 1992 Apr 5;224(3):685-99
pubmed: 1569550
Protein Sci. 2017 Dec;26(12):2399-2409
pubmed: 28960584
FEBS J. 2019 Jun;286(12):2381-2398
pubmed: 30903741
J Cell Physiol. 2019 Feb 6;:
pubmed: 30724341
Protein Sci. 2020 Feb;29(2):509-520
pubmed: 31697419
Trends Biochem Sci. 2017 Nov;42(11):862-872
pubmed: 28964625

Auteurs

Fedir Bokhovchuk (F)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Yannick Mesrouze (Y)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Clara Delaunay (C)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Typhaine Martin (T)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Frédéric Villard (F)

Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Marco Meyerhofer (M)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Patrizia Fontana (P)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Catherine Zimmermann (C)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Dirk Erdmann (D)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Pascal Furet (P)

Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Clemens Scheufler (C)

Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Tobias Schmelzle (T)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Patrick Chène (P)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH